The incidence of histoplasmosis appears to be higher in patients treated with anti-TNF monoclonal antibodies (e.g., infliximab) than in patients receiving soluble TNF-α receptors (e.g., etanercept) [33]. The gene discussed is TNF; the disease is histoplasmosis.